AASM Releases New Guidelines on Combination Treatment for Chronic Insomnia

The new guidelines focus on practical scenarios in clinical practice, acknowledging that patients often seek both cognitive behavioral therapy for insomnia (CBT-I) and pharmacotherapy. The guidance emphasizes the importance of incorporating patient preferences, which were less addressed in earlier versions.

The experts delved into the guideline development process, including the diverse backgrounds of committee members and their impact on the discussions. They highlighted the necessity of reflecting patient preferences adequately in the updated guidelines.

A key recommendation is that, for adults with chronic insomnia, the AASM suggests combination treatment with CBT-I and medication over medication alone, although this recommendation is conditional and based on low certainty of evidence. Dr. Buysse and Dr. Arnedt discussed medications assessed in the guidelines, including the role of dual orexin receptor antagonists (DORAs), while explaining the limitations arising from pharmaceutical sponsorship and high placebo effects in trials.

Questions about the implementation of combination therapy arose, such as whether treatments should commence simultaneously or sequentially, and whether patients can begin medication while waiting for CBT-I appointments, especially given typical access delays.

Another recommendation states that the AASM advises against combination treatment when compared to CBT-I alone, yet recommends combination therapy over medication alone. The experts provided context around this seemingly contradictory advice, clarifying that while CBT-I remains a superior option, combination therapy may suit patients seeking quick improvements in total sleep time despite delaying reductions in daytime symptoms.

The discussion further explored the ordering of treatments and examined whether insurers or clinical logic dictate a hierarchy of medications, such as the use of zolpidem before eszopiclone, and when to consider medications like trazodone or ramelteon.

The issue of patients who decline or lack access to CBT-I was also addressed, raising important considerations about applying these guidelines in such cases. Throughout the conversation, the emphasis remained on the importance of personalizing treatment plans according to patient values and circumstances, noting that the guidelines are intended to inform, not dictate, clinical decisions.

This episode serves as a valuable resource for clinicians dealing with chronic insomnia and navigating both patient requests for medications and accessibility barriers to CBT-I.